anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a Chinese patent medicine for treating herpes zoster. The medicine is prepared from the following raw medicinal materials in parts by weight: 15-20 parts of calamine, 15-20 parts of dried alum, 15-20 parts of golden cypress, 15-20 parts of indigo naturalis, 15-20 parts of rosin, and 15-20 parts of borneol. According to the medicine, the raw materials are selected and reasonable in compatibility and complementary in effects, and can play a good complementary effect. Clinical application indicates that the Chinese patent medicine can treat both manifestation and root cause of herpes zoster, and prevents relapse after healing, and is firm in curative effect, the total effective rate of the Chinese patent medicine can be over 95 percent. The Chinese patent medicine is a pure traditional Chinese medicinal product, is safe and low in treatment cost, and is quick in response, and can take effect in 1-2 courses of treatment generally. The patients feel little pains and do not have drug resistance after the Chinese patent medicine is taken, and the Chinese patent medicine is small in toxic and side effect, can be easily accepted by the patients, and overcomes the defects of toxic and side effects generated by taking western medicines in large dosages.
BACKGROUND: The prescription of levetiracetam during pregnancy has become more common due to its lower teratogenic risk profile. However, due to a lack of data about its association with stillbirth and spontaneous abortion, worries remain.
OBJECTIVE: To investigate information on any possible association of spontaneous abortion and stillbirth adverse events with levetiracetam in women with epilepsy.
METHODS: This retrospective pharmacovigilance study used disproportionality analysis to detect signals of adverse reaction of interest reported with Levetiracetam in FAERS, the FDA Adverse Event Reporting System. The ratio of reporting odds (ROR) and information component (IC) indices were used to undertake disproportionality analyses, and change point analyses were carried out to identify variations in the frequency of reporting of relevant adverse events. Sensitivity analyses included subgroup analyses by indication, treatment regimen, and reporting region.
RESULTS: Overall, 2870 cases of spontaneous abortion and stillbirth with commonly used antiseizure medications were analyzed. A total of 65.5 % of these cases had epilepsy as the indication. In the entire dataset, we observed disproportionality signals of spontaneous abortion for 6 ASMs (levetiracetam, carbamazepine, lamotrigine, oxcarbazepine, topiramate, valproic acid) and disproportionality signals of stillbirth for 4 ASMs (levetiracetam, carbamazepine, lamotrigine, oxcarbazepine). In the epileptic population, disproportionality signals for stillbirth (ROR0.25 = 4.60; IC0.25 = 1.30) and spontaneous abortion (ROR0.25 = 3.98; IC0.25 = 1.20) in levetiracetam was identified. These disproportionality signals have been consistently robust over the past years, according to a temporal assessment of them. Sensitivity studies proved how reliable the findings were.
CONCLUSION: Using validated pharmacovigilance methods, we found significant disproportional signals for spontaneous abortion and stillbirth associated with levetiracetam. Of these, the signals for spontaneous abortion were observed after 2011 and for stillbirth after 2014, which may be related to the rise in levetiracetam prescriptions during pregnancy in recent years. The association of spontaneous abortion and stillbirth adverse events with levetiracetam and potential biases confounding this association merit further investigation.
Disclosed are compositions and methods of treating a cytokine mediated disease by inhibiting Sema7A with VLA-1. Also disclosed are methods to identify a compound that inhibits interaction of Sema7A with VLA-1. Such methods involve (1) contacting a cell with a putative regulatory compound; and (2) assessing the ability of the compound to inhibit the interaction of Sema7A with VLA-1. Step (1) may employ a cell that includes a Sema7A  protein and a VLA-1 protein. Step (1) may also employ a cell that includes a Sema7A  protein, and the cell is contacted with the compound and VLA-1. Step (1) may also employ a cell that includes a VLA-1 protein, and the cell is contacted with the compound and Sema7A.
NEW MATERIAL:The compound of formula I [R1 is lower alkyl such as CH3, C2H5, etc.; R2-R4 are H, lower alkyl or (substituted) phenyl; Y is OH, OM (M is metal such as Na, K, etc.) or NH2]. EXAMPLE:The compound of formula II. USE:An opioid decomposition enzyme inhibitor for th effective utilization of morphine, etc., in living body, and an antibacterial agent. PREPARATION:For example, the compound of formula I (Y is OH) is produced by reacting the compound of formula III (X is halogen) (e.g. 3- trichlorogermylpropionic acid) with the compound of formula R1MgBr (e.g. methyl magnesium iodide). The product can be converted to another compound of formula I (Y is OM) by reacting with a metal hydroxide such as sodium hydroxide. Other compound of formula I (Y is NH2) is produced by converting the product to an acid halide and reacting with ammonia.
The primary goal of this study is to investigate the feasibility of implementing a prospective sepsis subphenotyping tool in the electronic health record and evaluating the characteristics and outcomes of the sepsis subphenotypes. During this study, clinicians will not see the results of the algorithm or have access to its predictions. Instead, the algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED). For each patient, the probability of subphenotype membership over the first 8 hours of presentation to the ED will be calculated using an algorithm previously validated on retrospective data. Differences in clinical characteristics and outcomes between the subphenotypes will be compared. Investigators will seek to classify 1,200 patients with suspected infections. Since it will not be apparent on ED presentation who has suspected infection, all patients will be classified into subphenotypes using the algorithm, but the primary subgroup who will be analyzed will be patients with suspected infection.
Systems and methods for non-invasive and/or non-contact measurement of a subject's tremor in the context of therapeutic intervention is presented. The system includes a memory, a communications interface, a sensor to measure a signal associated with position or motion of an extremity of the subject, and a processor. The processor is configured to receive the signal from the sensor. The processor is further configured to communicate, via the communications interface, the signal, login credentials, and position or motion data to a remote server coupled to a remote electronic health record database. The remote server is configured to receive the signal from the sensor. The processor is configured to receive an analysis that quantified the severity of tremor.
The invention discloses imidazobenzothiazole-derived fluconazole analogues described in formula I. The invention also discloses a preparation method of such kind of compounds and has the advantages of being short in synthetic route, high in the degree of raw material commercialization, low in cost, easy to obtain and simple in method. The imidazobenzothiazole-derived fluconazole analogues have certain inhibition activities to a part of gram positive bacteria, gram negative bacteria and fungi, and are capable of being used in preparing potential anti-bacterial and/or anti-fungal drug molecules. The R1, R2, R3, R4, R5, R6, X1, X2, X3 and Im in the universal molecular formula are defined in the claims.(The formula is shown in the description.).
The invention discloses an emulsion for efficiently encapsulating resveratrol and application thereof, belonging to the technical field of food processing. The preparation method comprises the steps of firstly, screening peppermint essential oil (PO) as a green dispersing agent of resveratrol, taking a mixture of PO and sunflower seed oil in any proportion as an internal oil phase, taking an aqueous solution of sodium caseinate as a continuous phase, and preparing the resveratrol-containing nano-emulsion through a two-step emulsification process of high-speed shearing and high-pressure homogenization. The nano-emulsion of the invention has good storage stability. When PO content is 50% or more, the retention rate of resveratrol is 80% or more after storage for 60 days at 45 ℃, and the resveratrol protective agent has a good protective effect on resveratrol. The emulsion of the invention does not introduce any organic reagent, has simple and convenient operation, is easy to industrialize and has the advantage of green production. Meanwhile, the emulsion is also applicable to the encapsulation and protection of fat-soluble functional factors, and has the advantage of wide application range.
Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
BACKGROUND: Vascular endothelial damage is involved in the development and exacerbation of ventilator-induced lung injury (VILI). Pulmonary endothelial glycocalyx and neutrophil extracellular traps (NETs) are endothelial protective and damaging factors, respectively; however, their dynamics in VILI and the effects of recombinant thrombomodulin and antithrombin on these dynamics remain unclear. We hypothesized that glycocalyx degradation and NETs are induced by VILI and suppressed by recombinant thrombomodulin, recombinant antithrombin, or their combination.
METHODS: VILI was induced in male C57BL/6J mice by intraperitoneal lipopolysaccharide injection (20 mg/kg) and high tidal volume ventilation (20 mL/kg). In the intervention groups, recombinant thrombomodulin, recombinant antithrombin, or their combination was administered at the start of mechanical ventilation. Glycocalyx degradation was quantified by measuring serum syndecan-1, fluorescence-labeled lectin intensity, and glycocalyx-occupied area in the pulmonary vascular lumen. Double-stranded DNA in the bronchoalveolar fluid and fluorescent areas of citrullinated histone H3 and myeloperoxidase were quantified as NET formation.
RESULTS: Serum syndecan-1 increased, and lectin fluorescence intensity decreased in VILI. Electron microscopy revealed decreases in glycocalyx-occupied areas within pulmonary microvessels in VILI. Double-stranded DNA levels in the bronchoalveolar lavage fluid and the fluorescent area of citrullinated histone H3 and myeloperoxidase in lung tissues increased in VILI. Recombinant thrombomodulin, recombinant antithrombin, and their combination reduced glycocalyx injury and NET marker levels. There was little difference in glycocalyx injury and NET makers between the intervention groups.
CONCLUSION: VILI induced glycocalyx degradation and NET formation. Recombinant thrombomodulin and recombinant antithrombin attenuated glycocalyx degradation and NETs in our VILI model. The effect of their combination did not differ from that of either drug alone. Recombinant thrombomodulin and antithrombin have the potential to be therapeutic agents for biotrauma in VILI.
BACKGROUND: Long-term invasive mechanical ventilation (IMV) is a major burden for those affected and causes high costs for the health care system. Early risk assessment is a prerequisite for the best possible support of high-risk patients during the weaning process. We aimed to identify risk factors for long-term IMV within 96 h (h) after the onset of IMV.
METHODS: The analysis was based on data from one of Germany's largest statutory health insurance funds; patients who received IMV ≥ 96 h and were admitted in January 2015 at the earliest and discharged in December 2017 at the latest were analysed. OPS and ICD codes of IMV patients were considered, including the 365 days before intubation and 30 days after discharge. Long-term IMV was defined as evidence of invasive home mechanical ventilation (HMV), IMV ≥ 500 h, or readmission with (re)prolonged ventilation.
RESULTS: In the analysis of 7758 hospitalisations, criteria for long-term IMV were met in 38.3% of cases, of which 13.9% had evidence of HMV, 73.1% received IMV ≥ 500 h and/or 40.3% were re-hospitalised with IMV. Several independent risk factors were identified (p < 0.005 each), including pre-diagnoses such as pneumothorax (OR 2.10), acute pancreatitis (OR 2.64), eating disorders (OR 1.99) or rheumatic mitral valve disease (OR 1.89). Among ICU admissions, previous dependence on an aspirator or respirator (OR 5.13), and previous tracheostomy (OR 2.17) were particularly important, while neurosurgery (OR 2.61), early tracheostomy (OR 3.97) and treatment for severe respiratory failure such as positioning treatment (OR 2.31) and extracorporeal lung support (OR 1.80) were relevant procedures in the first 96 h after intubation.
CONCLUSION: This comprehensive analysis of health claims has identified several risk factors for the risk of long-term ventilation. In addition to the known clinical risks, the information obtained may help to identify patients at risk at an early stage. Trial registration The PRiVENT study was retrospectively registered at ClinicalTrials.gov (NCT05260853). Registered at March 2, 2022.
Dental bleaching devices in the shape of a dental tray, strip or patch include a barrier layer, a dental bleaching composition, and a protective adhesive composition that protects a person's gums from the dental bleaching composition during use. The barrier layer protects the bleaching and protective adhesive compositions from saliva or moisture during use. The dental bleaching composition is positioned so as to contact a person's tooth surfaces when the bleaching device is in use. The protective adhesive composition is positioned so as to shield a person's gums from the bleaching composition when the bleaching device is in use. The dental bleaching composition and protective adhesive composition can be in the form of a gel or they may be substantially solid. They preferably include a tissue adhesion agent comprising a hydrophilic polymer.
A moisture-proof assembly for keeping away from a moisture comprises a housing, a cover, a physiological signal transmitter, a charging device and a desiccant. The housing has an opening. The cover is detachably disposed on the housing, configured to seal the opening, and forms an accommodating space together with the housing. The physiological signal transmitter is disposed in the accommodating space for measuring and transmitting a physiological signal. The charging device is combined with the physiological signal transmitter and disposed together or the charging device and the physiological signal sensor are separate disposed in the accommodating space. The desiccant is disposed in the accommodating space to prevent the physiological signal transmitter from moisture, wherein when the physiological signal transmitter is in need of being charged, the charging device is taken out of the accommodating space, and connected to an external power source to charge the physiological signal transmitter.
The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
VLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
This study proposed is a double-blind, placebo-controlled, phase III randomized controlled trial powered to detect meaningful differences in the overall health and symptom severity of people with COVID-19 between the treatment and control arms. Eligible participants will be randomly assigned, using a web randomization system, in a ratio of 1:1 to one of the following groups: (1) nutrient therapy with vitamin D, vitamin C, vitamin K2, and zinc or (2) placebo. Total trial duration will be 12 weeks. Nutrients or placebo will be given for a period of 21 days following enrolment and randomization. Total trial duration will be 12 weeks. Adverse events will be collected during the treatment phase plus one additional week (maximum 4 weeks).

With respect to the primary outcome of participant-reported overall health, power calculations were conducted based on between-group differences at a single time point (21 days) and Cohen's guideline for a small effect size of 0.3. A sample size of 176 (88 per arm) provides 80% power to detect a difference at an α of 0.05. To account for an approximate 10-15% lost to follow-up we will enrol 200 participants (100 per arm).
EN1 encodes a homeodomain-containing transcription factor and is a determinant of bone density and fracture. Previous powerful genome-wide association studies (GWASs) have identified multiple single-nucleotide polymorphisms (SNPs) near EN1 at 2q14.2 locus for osteoporosis, but the causal SNPs and functional mechanisms underlying these associations are poorly understood. The target genes regulated by the transcription factor EN1 are also unclear. In this study, we identified rs188303909, a functional CpG-SNP, as a causal SNP for osteoporosis at 2q14.2 through the integration of functional and epigenomic analyses. Functional experiments demonstrated that unmethylated rs188303909 acted as a strong allele-specific distal enhancer to regulate EN1 expression by modifying the binding of transcription factor E2F6, but rs188303909 methylation attenuated the active effect of E2F6 on EN1 expression. Importantly, transcription factor EN1 could differentially bind osteoporosis GWAS lead SNPs rs4869739-T and rs4355801-G to upregulate CCDC170 and COLEC10 expression, thus promoting bone formation. Our study provided a mechanistic insight into expression regulation of the osteoporosis susceptibility gene EN1, which could be a potential therapeutic target for osteoporosis precision medicine. KEY MESSAGES: CpG-SNP rs188303909 is a causal SNP at the osteoporosis susceptibility locus 2q14.2. Rs188303909 distally regulates EN1 expression by modulating DNA methylation and E2F6 binding. EN1 upregulates CCDC170 and COLEC10 expression through osteoporosis GWAS lead SNPs rs4869739 and rs4355801.
BACKGROUND: There is a lack of guidance on approaches to formulary management and funding for high-cost drugs and therapeutics by individual healthcare institutions. The objective of this review was to assess institutional approaches to resource allocation for such therapeutics, with a particular focus on paediatric and rare disease populations.
METHODS: A search of Embase and MEDLINE was conducted for studies relevant to decision-making for off-formulary, high-cost drugs and therapeutics. Abstracts were evaluated for inclusion based on the Simple Multiple-Attribute Rating Techniques (SMART) criteria. A framework of 30 topics across 4 categories was used to guide data extraction and was based on findings from the initial abstract review and previous health technology assessment (HTA) publications. Reflexive thematic analysis was conducted using QSR NVivo 12 software.
RESULTS: A total of 168 studies were included for analysis. Only 4 (2%) focused on paediatrics, while 21 (12%) centred on adults and the remainder (85%) did not specify. Thirty-two (19%) studies discussed the importance of high-cost therapeutics and 34 (23%) focused on rare/orphan drugs. Five themes were identified as being relevant to institutional decision-making for high-cost therapeutics: institutional strategy, substantive criteria, procedural considerations, guiding principles and frameworks, and operational activities. Each of these themes encompassed several sub-themes and was complemented by a sixth category specific to paediatrics and rare diseases.
CONCLUSION: The rising cost of novel drugs and therapeutics underscores the need for robust, evidence-based, and ethically defensible decision-making processes for health technology funding, particularly at the hospital level. Our study highlights practices and themes to aid decision-makers in thinking critically about institutional, substantive, procedural, and operational considerations in support of legitimate decisions about institutional funding of high-cost drugs and therapeutics, as well as opportunities and challenges that exist for paediatric and rare disease populations.
Described here are self-expanding devices and methods of using and making them. The devices may be useful in a variety of locations within the body, for a number of different uses. In some variations, the devices have a first compressed configuration enabling low profile delivery through a delivery device, a second expanded configuration for apposition against tissue, and comprise either a single continuous filament or at least two non-intersecting filaments. In some variations, the device is formed into a shape having a series of peaks and valleys. At least one of the peaks and valleys may have a loop at then end thereof. At least a portion of these devices may be capable of biodegrading over a predetermined period of time, and the devices may be configured for drug delivery. Methods of treating one or more sinus cavities are also described here.
BACKGROUND: Malnutrition is a state resulting from lack of intake or uptake of nutrition. Investigating the association between malnutrition and postoperative complications is essential for enhancing patient outcomes in total joint arthroplasty (TJA). This meta-analysis aimed to investigate the impact of malnutrition on the incidence of surgical site infections (SSIs) and periprosthetic joint infections (PJIs) following TJA.
METHODS: The data were searched from databases including PubMed, Embase, Web of Science, and Cochrane Library inception through July 19 2023, without time restrictions. Inclusion criteria focused on studies examining malnutrition as a risk factor for SSIs and PJIs postarthroplasty, providing sufficient data for calculating odds ratios (ORs) and 95% confidence intervals (CIs). Methodological quality was assessed using the Newcastle‒Ottawa Scale, and statistical analyses were executed in Stata version 17.
RESULTS: A total of 1,025 articles were screened, and 9 studies satisfying the predefined inclusion criteria were consequently selected for this meta-analysis. Studies indicated that malnutrition is significant factor to the heightened incidence of both SSIs and PJIs following TJA procedures. Our pooled results yielded aggregated ORs of 2.60 for SSIs and 3.44 for PJIs, with respective 95% CIs of 2.10-3.10 and 2.35-4.53. The heterogeneity of malnutrition as a risk factor for postoperative SSI was I2 = 0.0% (p = 0.592), and for PJI was I2 = 0.0% (p = 0.422). Egger's linear regression test showed no significant publication bias (p > 0.05).
CONCLUSIONS: Malnutrition is a significant risk factor for SSIs and potentially PJIs in patients undergoing TJA. Preoperative optimization strategies targeted at malnourished patients are suggested to minimize postoperative complications clinically.